MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.8700
-0.0600 (-1.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9300
Open3.9400
Bid3.7400 x 800
Ask3.8800 x 1100
Day's Range3.7350 - 4.1400
52 Week Range1.6200 - 30.0000
Volume949,457
Avg. Volume2,601,776
Market Cap45.588M
Beta (3Y Monthly)6.01
PE Ratio (TTM)N/A
EPS (TTM)-14.7390
Earnings DateAug 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • Melinta (MLNT) Announces Preliminary Product Sales for Q2
    Zacks3 days ago

    Melinta (MLNT) Announces Preliminary Product Sales for Q2

    Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.

  • GlobeNewswire4 days ago

    Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today reported preliminary and unaudited financial results and provided a corporate update for the second quarter ended June 30, 2019. “Melinta’s preliminary second quarter 2019 results demonstrate that the actions taken to improve upon the Company's operational and financial efficiencies are continuing to drive progress,” said John H. Johnson, chief executive officer of Melinta.

  • Benzinga15 days ago

    Make Trend Your Friend With This Volume-Focused Trading Tool

    Given July’s notoriously slow trading environment, I wanted to spend this week’s article breaking down another massively useful trading tool that can signal the trajectory and strength of a stock’s price trend, Volume Weighted Average Price, or VWAP. Like it says on the tin, VWAP is a weighted average of a stock’s trading price that emphasizes price points with the most amount of transactions. VWAP is calculated by taking the average trading price on a single candle and multiplying it by the total number of trades in that candle.

  • PR Newswire19 days ago

    X-Biotix Therapeutics Joins Antimicrobials Working Group

    WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...

  • Benzingalast month

    A Look At Benzinga Pro's Most-Searched Tickers For June 20, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Melinta Therapeutics, Inc. (NASDAQ: MLNT ) ...

  • PR Newswirelast month

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

    64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • Options Traders Expect Huge Moves in Melinta Therapeutics (MLNT) Stock
    Zackslast month

    Options Traders Expect Huge Moves in Melinta Therapeutics (MLNT) Stock

    Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.

  • Melinta Therapeutics News: Why MLNT Stock Is Skyrocketing Today
    InvestorPlacelast month

    Melinta Therapeutics News: Why MLNT Stock Is Skyrocketing Today

    Melinta Therapeutics news for Wednesday concerning approval from the U.S. Food and Drug Administration (FDA) has MLNT stock flying high.Source: Shutterstock Melinta Therapeutics (NASDAQ:MLNT) says that it now has approval from the FDA for a supplemental New Drug Application. This supplemental New Drug Application is for expanding the use of the company's BAXDELA drug.BAXDELA is a drug made by Melinta Therapeutics that treats acute bacterial skin and skin structure infections. It first got approval from the FDA in 2017. Now MLNT is seeking to also use the drug to treat adults that are dealing with community-acquired bacterial pneumonia.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSue Cammarata, M.D., Chief Medical Officer of MLNT, has this to say about the Melinta Therapeutics news."Due to the rise of antibiotic resistance and an aging population, community-acquired bacterial pneumonia, or CABP, remains a challenge for healthcare professionals and has led to a need for new treatment options. BAXDELA's potency and activity against the most common bacterial pathogens seen in CABP indicate it could play a significant role in the treatment of this life-threatening illness, if approved. We look forward to working with the FDA to help evaluate bringing this potential option to people with CABP as soon as possible." * 7 Value Stocks to Buy for the Second Half The Melinta Therapeutics news of approval from the FDA gives the supplemental New Drug Application a priority review status. The organization has set a review deadline for the application of Oct. 24, 2019.MLNT stock was up 190% as of Wednesday afternoon. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Melinta Therapeutics News: Why MLNT Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • MarketWatchlast month

    Melinta Therapeutics' stock rockets on heavy volume after FDA accepts sNDA for Baxdela

    Shares of Melinta Therapeutics Inc. more than doubled (up 128%) on heavy volume Wednesday, after the antibiotics developer said its supplemental new drug application (sNDA) for Baxdela was accepted by the U.S. Food and Drug Administration. Trading volume spiked to over 4.7 million shares, compared with the full-day average of about 334,000 shares through Tuesday, and enough to make the stock the most actively traded ahead of the open. The company said the FDA has granted "priority review" status for Baxdela, in which the sNDA seeks to expand the current indication to include adult patients with community-acquired bacterial pneumonia (CABP). "BAXDELA's potency and activity against the most common bacterial pathogens seen in CABP indicate it could play a significant role in the treatment of this life-threatening illness, if approved," said Melinta Chief Medical Officer Sue Cammarata. "We look forward to working with the FDA to help evaluate bringing this potential option to people with CABP as soon as possible." The stock has tumbled 50% year to date through Tuesday, while the S&P 500 has gained 16%.

  • GlobeNewswirelast month

    Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for BAXDELA® (delafloxacin) for priority review. The sNDA filing seeks to expand the current indication for BAXDELA to include adult patients with community-acquired bacterial pneumonia (CABP). The FDA granted priority review status based on the previous Qualified Infectious Disease Product (QIDP) designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections.

  • Those Who Purchased Melinta Therapeutics (NASDAQ:MLNT) Shares A Year Ago Have A 96% Loss To Show For It
    Simply Wall St.last month

    Those Who Purchased Melinta Therapeutics (NASDAQ:MLNT) Shares A Year Ago Have A 96% Loss To Show For It

    As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...

  • PR Newswirelast month

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 14.29% and -16.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Melinta Therapeutics, Inc.: 1Q Earnings Snapshot

    On a per-share basis, the New Haven, Connecticut-based company said it had a loss of $2.34. The drugmaker posted revenue of $14.1 million in the period. In the final minutes of trading on Thursday, the ...

  • GlobeNewswire2 months ago

    Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    ~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million,.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, including results from its real-world registry studies of VABOMERE® (meropenem and vaborbactam), ORBACTIV® (oritavancin), and MINOCIN® (minocycline) for Injection at the upcoming Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting held from May 8-11 2019 in Orlando, Florida. "Our presentations demonstrate Melinta’s continued commitment to combatting antimicrobial resistance by helping to inform clinical decision-making for the responsible and sustainable use of our antibiotics,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GlobeNewswire3 months ago

    Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019 financial results on May 9, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Thursday, May 9, 2019, at 4:30 p.m. ET to discuss its financial results and provide a business update. On May 9, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #5233509.

  • PR Newswire3 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire3 months ago

    Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands. “The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GuruFocus.com4 months ago

    Melinta Therapeutics Inc (MLNT) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Melinta Therapeutics Inc (NASDAQ:MLNT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire4 months ago

    Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

    ~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018,.

  • GlobeNewswire5 months ago

    Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to discuss its financial results and provide a business update. On March 13, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #1698998.

  • TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
    Zacks5 months ago

    TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%

    TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • GlobeNewswire5 months ago

    Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding

    MORRISTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) --  Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the closing and receipt of the initial $75 million disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. In addition, the previously announced amendment to the facility agreement with funds managed by Deerfield Management Company, L.P. (collectively, “Deerfield”) also became effective.